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2ABSTRACT 
Thymic senescence contributes to increased incidence of infection, cancer and autoimmunity
at senior ages. This process manifests as adipose involution. As with other adipose tissues,
thymic adipose involution is also controlled by PPARgamma. This is supported by
observations reporting that systemic PPARgamma activation accelerates thymic adipose
involution. Therefore we hypothesized that decreased PPARgamma activity could prevent
thymic adipose involution, although it may trigger metabolic adverse effects. 
We have confirmed that both human and murine thymic sections show marked staining for
PPARgamma at senior ages. We have also tested the thymic lobes of PPARgamma haplo-
insufficient and null mice. Supporting our working hypothesis both adult PPARgamma haplo-
insufficient and null mice show delayed thymic senescence by thymus histology, thymocyte
mTrec qPCR and peripheral blood naïve T-cell ratio by flow-cytometry. Delayed senescence
showed dose-response with respect to PPARgamma deficiency. Functional immune
parameters were also evaluated at senior ages in PPARgamma haplo-insufficient mice (null
mice do not reach senior ages due to metabolic adverse affects). As expected, sustained and
elevated T-cell production conferred oral tolerance and enhanced vaccination efficiency in
senior PPARgamma haplo-insufficient, but not in senior wild-type littermates according to
ELISA IgG measurements. 
Of note, humans also show increased oral intolerance issues and decreased protection by
vaccines at senior ages. Moreover, PPARgamma haplo-insufficiency also exists in human
known as a rare disease (FPLD3) causing metabolic adverse effects, similar to the mouse.
When compared to age- and metabolic disorder-matched other patient samples (FPLD2 not
affecting PPARgamma activity), FPLD3 patients showed increased hTrec values by qPCR
(within healthy human range) suggesting delayed thymic senescence, in accordance with
mouse results and supporting our working hypothesis.
In summary our experiments prove that systemic decrease of PPARgamma activity prevents
thymic senescence, albeit with metabolic drawbacks. However, thymic tissue-specific
PPARgamma antagonism would likely solve the issue.
Keywords: PPARgamma, thymus, immunity, senescence, rejuvenation
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31. INTRODUCTION
The PPAR (peroxisome proliferator-activated receptor) molecular family is widely studied (1-
3). These nuclear receptor proteins possess transcription factor activities and influence
multiple cellular events at the molecular level including adipocyte differentiation and
metabolism. Among them, PPARgamma is of particular interest being expressed by all
adipose tissue subtypes and being indispensable for adipose tissue development and for the
homeostasis of physiological metabolism (4-7). As a consequence, in the mouse systemic loss
of PPARgamma activity severely impairs glucose and lipid metabolism as characterized by
others (8-10). In accordance, PPARgamma null mice are only viable if using conditional
knockout strategy (11). Similar to the mouse above, in human PPARgamma haplo-
insufficiency leads to the development of a rare metabolic condition known as familial partial
lipodystrophy, type 3 (FPLD3, ORPHA 79083) also characterized by diabetes and
dyslipidemia (12-15). 
In mammals systemic PPARgamma activity may be increased at multiple levels.
Environmental factors including excessive caloric consumption or corticosteroid exposure
increase PPARgamma activity systemically (16-18). Pharmacological systemic activation may
be achieved through administration of thiazolidinediones (TZDs) previously used as part of
oral anti-diabetic treatment, but currently neglected due to adverse cardiovascular side-effects
(19, 20). Genetic engineering-based enhancement of PPARgamma activity in mouse models
has also been performed (21). In every case increased PPARgamma activity promotes adipose
tissue development at multiple sites of the body.
Thymic aging is observed as adipose involution during which the functional thymus niche that
normally supports T-cell production is gradually lost and replaced by adipose tissue (22). The
process starts focally in childhood then spreads and accelerates with puberty due to hormonal
changes (23). Diminishing T-cell production results in decreased availability of fresh naïve T-
cells (24). Consequences include increasing incidence of infection, cancer and autoimmunity
observed at senior ages (25, 26). Thymic adipose involution appears to be PPARgamma-
dependent: any condition that systemically enhances PPARgamma activity – either
environmental, pharmacological or genetic – accelerates thymic senescence or adipose
involution with all its immunological consequences (27-32). However, the opposite
phenomenon whether systemically decreased PPARgamma activity can ameliorate long-term
functional immune parameters has barely been addressed (33, 34). For this reason we have set
out to characterize the effect of systemic genetic PPARgamma loss of function on long-term
immune homeostasis in both mouse and human.
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42. METHODS
2.1. Human thymus samples
Formalin-fixed, paraffin-embedded (FFPE) human thymus samples from age groups 30-40
years 50-60 and 70-80 years were obtained from the Department of Pathology (Faculty of
Medicine, University of Pecs, Hungary.) Experiments involving human thymus samples were
performed with the consent of the Regional and Local Ethics Committee of Clinical Centre,
University or Pecs (ref. no.: 6331/2016) according to their guidelines. All subjects gave
written informed consent in accordance with the Declaration of Helsinki.
2.2. Human immunohistochemistry
Human thymus lobes were fixed in paraformaldehyde (4% PFA in PBS) then paraffin
embedded. 5µm thick sections were stained using immunohistochemistry (35). First the slides
were rinsed in heated xylene and were washed with a descending series of alcohol to remove
paraffin. After de-paraffination the slides were rehydrated in distilled water and antigen
retrieval was performed by heating the slides in Target Retrieval Solution (pH 6 DAKO) at
97°C for 20-30 minutes. Subsequently slides were washed in dH2O and endogenous
peroxidase activity was blocked with 3% H2O2 containing TBS (pH 7.4) for 15 minutes. Then
slides were washed three times with TBS containing Tween (0.05%, pH 7.4). Pre-blocking
was carried out with 3% BSA in TBS for 20 minutes before overnight incubation with anti-
PPARgamma (1:100, rabbit monoclonal antibody clone: C26H12 Cell Signalling Technology)
primary antibody at 4°C. Following incubation slides were washed with TBS for three times
then incubated with peroxidase conjugated secondary antibody (1:100, Polyclonal Goat Anti-
Rabbit IgG, DAKO) for 90 minutes. Antibody labeling was visualized with the help of liquid
DAB Substrate Chromogen System (DAKO). For nuclear counterstaining hematoxylin
staining was performed. Finally slides were mounted with Faramount Aqueous Mounting
Medium (DAKO). Histological evaluation was performed with the help of Panoramic MIDI
digital slide scanner (3DHistech). Image analysis was performed using ImageJ software with
IHC toolbox plug-in. 
2.3. Mouse breeding and maintenance
For certain experiments we have used wild-type and PPARgamma heterozygous (haplo-
insufficient) or PPARgamma null (KO) mice of C57BL/6J genetic background. The mice
were age matched, and both genders were used for the investigation. The design to generate
PPARgamma KO mice was described previously (11). Briefly, PPARgamma +/-/Sox2Cre+
male mice were crossed with PPARgamma fl/fl female mice to generate heterozygous
PPARgamm afl/-/Sox2Cre- and homozygous PPAR gammaΔfl/-/Sox2Cre+ mice, wherein the
floxed allele was recombined resulting a null allele. Mice were housed under minimal disease
(MD) conditions in the Laboratory Animal Core Facility of University of Debrecen. Animal
rooms were ventilated 15 times / hour with filtered air, mice received autoclaved pellet diet
(Altromin VRF1) and tap water ad libitum. The cages contained sterilized bedding. Room
lightning was automated with 12 hours light and 12 hours dark periods. The room temperature
was 21±2 °C, the relative humidity is between 30-60%. Senescent animals developed and
aged normally, without any treatment. Permission to perform the described animal
experiments was granted to the relevant utilities of the University of Pecs (ref. no.:
BA02/2000-46/2016). Permission to generate PPARgamma GM mice was granted to the
relevant utilities of the University of Debrecen (ref. no.: TMF/82-10/2015). Permission to
perform experimental procedures with PPARgamma GM mice was granted to the relevant
utilities of the University of Pecs (ref. no.: TMF/124-11/2017).
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52.4. Mouse immunofluorescence
Immunofluorescent staining was performed on 8µm cryo-sections of mouse thymus lobes as
described previously (35). Briefly, the slides were fixed in cold acetone, then dried and
blocked to prevent non-specific staining using 5% BSA in PBS for 20 min before staining
with fluorochrome-conjugated or primary antibodies: anti-EpCAM1-FITC (1:100, rat
monoclonal antibody clone: G8.8,), anti-Ly51-PE (1:100, rat monoclonal antibody clone:
6C3, eBioscience), anti-PPARgamma (rabbit monoclonal antibody clone: C26H12 Cell Cell
Signaling Technology). For secondary antibody Alexa-555 conjugated a-rabbit goat IgG
(1:200, Life Technologies) was used. In certain cases DAPI (Life Technologies) nuclear
counterstain was also applied. Sections were analyzed using a Nikon Eclipse Ti-U microscope
equipped with a CCD camera (Andor Zyla 5.5) and NIS-Elements software. The
medulla/cortex ratio was calculated using ImageJ software.
2.5. Mouse flow-cytometry
Thymocyte subsets and T-cell subpopulations in blood were investigated by flow-cytometry
as published by others (36, 37). Thymocytes and PBMC were isolated from mice and labeled
with fluorophore-conjugated antibodies in PBS-BSA (5% BSA diluted in PBS). In every case
100,000 cells were stained for measurement. Incubation with antibodies was performed at 4°C
for 60 minutes followed by a washing step. FACSCanto II flow-cytometer and FACSDiva
software (Becton Dickinson) were used for analysis. In every case 10,000 events (parent R1
morphological lymphocyte gate) were recorded by flow-cytometry. For thymocyte subset
measurement Alexa-647 conjugated anti-mouse CD4 (clone: YTS 191) and FITC conjugated
anti-mouse CD8 (clone: IBL 3/25) antibodies were used (both produced in the Department of
Immunology and Biotechnology, University of Pecs, Hungary). For peripheral blood T cell
subpopulation analysis, Pacific Blue conjugated anti-mouse CD3 (clone: 17A2), PerCP
conjugated anti-mouse CD4 (clone: GK1.5), APC/Cy7 conjugated anti-mouse CD8 (clone:
YTS156.7.7), PE conjugated anti-mouse CD44 (clone: IM7), APC conjugated anti-mouse
CD62L (clone: MEL-14) (all purchased form BioLegend) and FITC conjugated anti-mouse
CD19 (clone: 1D3, produced by the Department of Immunology and Biotechnology,
University of Pecs, Hungary) were used.
2.6. TREC measurement by digital qPCR in mouse and human
TREC (T-cell recombination excision circle) by-products of gene-rearrangement in fresh
naive T-cells were also assessed. We performed mTREC digital qPCR using mouse and
hTREC digital qPCR using human samples by adapting methods published by others (38).
Briefly, DNA was isolated from mouse thymocytes using the NucleoSpin Tissue kit
(Macherey-Nagel) according to the manufacturer’s instruction. For human, peripheral-blood
samples were processed using the DNA Blood Mini kit (Qiagen) following the manufacturer’s
guides. Absolute copy numbers were measured by digital PCR on the QuantStudio 3D Digital
PCR platform (ThermoFisher) using 30 ng DNA per sample. Taqman primers / probes and
digital qPCR reagents were also purchased from ThermoFisher and used as suggested. For
age-matched range of healthy human hTrec values please refer to the work of Lynch et al (38).
Permission to perform the described animal experiments was granted to the relevant utilities
of the University of Pecs (ref. no.: BA02/2000-46/2016). Experiments involving human blood
samples were performed with the consent of the Regional and Local Ethics Committee of
Clinical Centre, University or Pecs (ref. no.: 6439/2016) according to their guidelines.
2.7. Oral tolerance induction in mouse
Induction and evaluation of oral tolerance was performed as described by others (39, 41, 42).
Briefly, both wild-type and PPARgamma haplo-insufficient mice received 5mg/ml ovalbumin
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6(OVA, Sigma-Aldrich) in drinking water for seven days. On day 7 mice were challenged with
an intra-peritoneal injection of 5μg ovalbumin in 200μl of 1:1 of PBS:complete Freund
adjuvant. On day 14 mice received an intra-peritoneal injection of 5μg ovalbumin in 200 μl of
1:1 of PBS:incomplete Freund adjuvant. Serum was collected on day 21 and anti-OVA IgG
antibodies were measured by ELISA. Briefly, 96 well Microtest Plates (Sarstedt) were coated
with OVA and blocked with BSA. Then plates were incubated with serial dilutions of mouse
serum samples (1:100 - 1:3200). The antibody content was visualized with the help of HRP
conjugated a-mouse immunoglobulin antibody (rabbit polyclonal, Dako). Optical density was
measured at 492 nm with iEMS Reader MF equipment (Thermo Labsystems).
2.8. Influenza vaccination in mouse
The efficiency of influenza vaccination was investigated as described elsewhere (40). Briefly,
both wild-type and PPARgamma haplo-insufficient mice were injected intramuscular once
with 0.1ml human seasonal influenza vaccine cocktail (3Fluart) to mimic human vaccination
at 9 months of age. In order to imitate human exposure pattern serum antibody IgG titer
against H1N1 A/California/7/2009 strain (part of 3Fluart) was measured by ELISA three
months after initial single vaccination at 12 months of age. For detection ELISA plates were
coated with 0.05ug HA protein of influenza strain A (Recombinant subtype H1N1
A/California/7/2009 His Tag, Life Technologies). Then plates were incubated with serial
dilutions of mouse serum samples (1:5 - 1: 1600). The antibody content was visualized with
the help of HRP conjugated a-mouse immunoglobulin antibody (rabbit polyclonal, Dako).
Optical density was measured at 492 nm with iEMS Reader MF equipment (Thermo
Labsystems).
2.9. Statistical analysis
All experiments were performed at least on three occasions, representative experiments are
shown. Measures were obtained in triplicates, data are presented as mean and +SD as error
bars. Graphpad Prism software was used for statistical analysis. Two-tailed T-student test was
applied. Significant differences are shown by asterisks (ns for not significant, * for p ≤ 0.05,
** for p ≤ 0.01, *** for p ≤ 0.001).
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73. RESULTS
3.1. PPARgamma distorts the ratio of thymic epithelial compartments with age
Previously reported mouse results showed increasing PPARgamma expression with age in the
thymic epithelial compartments, accompanied by thymic adipose involution. We have set out
to prove human relevance of previous mouse findings and test whether PPARgamma activity
influences the ratio of thymic epithelial compartments.
3.1.1. PPARgamma expression increases in the adult thymus with age
Human FFPE thymic sections were analyzed for their PPARgamma expression in several
adult age groups from young through middle-aged to senior (Figure 1A-D). Our results
indicate that PPARgamma expression significantly and progressively increases with age
(Figure 1A-C). Of note, total cellular areas shrink at senior ages in both human (Figure 1C)
and mouse (Figure 1F). As a result the ratio of PPARgamma-expressing cellular areas shows
relative increase with age (Figure 1D). Immunofluorescent staining of mouse thymic cryo-
sections at 15 months of age (Figure 1F) provides visual support for thymic epithelial to
adipose trans-differentiation in harmony with the working hypothesis of cellular trans-
differentiation. A portion of stromal cells shows dual staining for epithelial identity and
adipose differentiation, a hallmark of thymic adipose involution. This phenomenon is not
observed at young adult age (Figure 1E).
3.1.2. PPARgamma skews the ratio of epithelial compartments with age
Mouse thymic cryo-sections were differentially stained for medullary and cortical epithelial
compartments at several ages and using various genetic backgrounds (Figure 2A-D). Our
results show that in the wild-type setting the medullary epithelial compartment significantly
shrinks with age as reported previously (31). This, however, is not observed in PPARgamma
deficient settings. Loss of PPARgamma activity shows protection in a progressive manner
presenting dose-response (Figure 2E). PPARgamma deficiency efficiently and significantly
prevents the erosion of the medullary epithelial compartment, otherwise prone to shrink with
senescence.
3.2. PPARgamma affects thymic T-cell production and peripheral blood T-cell
distribution with age
We have observed changes in thymus architecture in response to PPARgamma status.
Consequently, we were interested in whether morphological changes alter thymus function:
naïve T-cell production. Going beyond, we were eager to see if sustained influence of
PPARgamma status on thymocyte function is also reflected in the peripheral blood.
3.2.1. PPARgamma disturbs thymic T-cell output with age
Age-related changes in thymocyte levels of mTrec (DNA loop by-product of mouse T-cell
receptor gene rearrangement) were evaluated in wild-type and PPARgamma deficient settings
using digital qPCR (Figure 3A). Our results indicate slight (though not significant) decrease
of mTrec and hence fresh-naïve T-cell output with age in thymocytes of wild-type mice.
PPARgamma deficiency significantly and progressively counteracts the process also showing
dose-responsive increase of thymocyte mTrec levels. In further analyses the percent
distribution of thymocyte subpopulations was assessed using flow-cytometry in wild-type and
PPARgamma deficient mice (Figure 3B). All thymocyte subpopulations showed near
identical distribution pattern with all genetic backgrounds. Taken together, PPARgamma
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8deficiency progressively enhances thymocyte development in adult age, but without skewing
the distribution of thymocyte subpopulations or their differentiation preference.
3.2.2. PPARgamma influences T-cell subpopulation distribution in adult peripheral blood
Peripheral blood T-cell subpopulations were evaluated by flow-cytometry at 12 months of age
in wild-type and PPARgamma deficient animals. Our results do not show differences in the
percent distribution of the major T-cell groups of helper T-cells and cytotoxic T-cells (Figure
4A) within the CD3-gate of T-cells. However, the evaluation of naive T-cell and memory T-
cell ratio reveals significant effect of PPARgamma deficiency (Figure 4B). There is
significant increase of naïve T-cells in the peripheral blood of PPARgamma deficient animals
compared to wild-type animals, conversely and significantly decreasing the memory T-cell
pool within the CD3-gate of T-cells. Deeper analysis of the memory T-cell pool reveals it is
the mobile effector memory T-cell subpopulation that shows significant decrease and not
central memory T-cells (Figure 4C) within the CD3-gate of T-cells. Sustained and prolonged
naïve T-cell production due to PPARgamma deficiency in the thymus as suggested by mTrec
values above apparently affects peripheral blood T-cell subpopulations as shown here.
3.3. Functional immunological consequence and human relevance
Having seen the far-reaching influence of PPARgamma status on thymus architecture, thymus
function and peripheral blood T-cell composition with age, we have set out to test whether
these changes have functional immunological relevance. If so, it would be also of high
interest to test if our comprehensive mouse results have human relevance.
3.3.1. PPARgamma modulates immune regulation and immune response
We have tested the capacity to mount oral tolerance to the foreign protein OVA in wild-type
and PPARgamma deficient aged adult mice by measuring OVA-specific IgG titers following
oral and / or intra-peritoneal OVA challenge (Figure 5A). As reported by others, age impairs
oral tolerance in wild-type animals (41, 42). As a consequence, there is only moderate,
insufficient decrease of OVA-specific IgG titers in case of parallel oral OVA administration
and i.p. OVA-injection in senior animals. However, PPARgamma deficiency rescues oral
tolerance in the same experimental setting despite of age, profoundly and significantly
decreasing OVA-specific IgG titers (Figure 5A). Consequently, naïve T-cell dependent
immune regulation (oral tolerance) remains efficient in PPARgamma heterozygous animals
despite their age. 
The capacity to mount immune reaction to foreign influenza antigens was also tested as
human seasonal influenza vaccine was injected into aged adult wild-type and PPARgamma
deficient animals. Subsequent analysis of serum IgG titers specific to a vaccine component
showed elevated protective antibody production (maximal ELISA OD values) in PPARgamma
deficient animals, but not in their wild-type littermates (Figure 5B). This tendency is not
significant because of individual variation observed due to the applied human vaccination
protocol being inferior to standard mouse immunization protocol. Nevertheless, naïve T-cell
dependent immune response proves to be efficient in aged, PPARgamma heterozygous
animals.
3.3.2. Human evidence of PPARgamma deficiency preventing thymic senescence
Genetic PPARgamma deficiency is a rare, but existing condition in human called FPLD3 (15).
It leads to a metabolic phenotype called lipodystrophy, similar to the mouse (11-15). Other
rare human conditions not affecting PPARgamma can also lead to lipodystrophy (12-15). In
case of FPLD2 lamin mutations trigger similar metabolic changes (14). Peripheral blood
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9hTrec (DNA loop by-product of human T-cell receptor gene rearrangement) levels were
measured using digital qPCR in age-matched patients with FPLD2 condition and FPLD3
condition (Figure 6). As expected and in perfect harmony with previous mouse thymocyte
results elevated mean hTrec levels were detected in FPLD3 samples compared to FPLD2
samples. The tendency is not significant due to individual variation within the patient groups.
Unfortunately, current patient sample numbers cannot be increased due to the extremely rare
nature of these conditions (FPLD2 or ORPHA 2348 has prevalence of ≤ 1/1,000,000 and
FPLD3 or ORPHA 79083 also has prevalence of ≤ 1/1,000,000) (14, 15). For age-matched
range of healthy human hTrec values please refer to the work of Lynch et al (38). Lower limit
of healthy human hTrec threshold (approx. 200 copies / mg DNA) is not reached by FPLD2
(lamin) patient samples, but this is rescued in FPLD3 (PPARgamma) patients despite being
age- and disease-matched.
1
2
3
4
5
6
7
8
9
10
11
12
13
1
1
0
4. DISCUSSION
4.1. PPARgamma drives thymic epithelial to adipose trans-differentiation with age
It has been previously suggested based on direct fate-mapping experiments that with
senescence thymic adipose tissue develops from the thymic stromal or epithelial compartment
(28). Based on indirect evidence others have also supported this concept (29). In further
support, we here present visual evidence of epithelial to adipose trans-differentiation in the
mouse. This is indicated by the presence by EpCAM-1 / PPARgamma double-positive cells
shown by histology (Figure 1D). These cells still express cell surface markers of their fading
thymic epithelial identity (EpCAM-1), but already show early signs of the novel adipocyte
differentiation program in their nuclei (PPARgamma). The fact that such double positive cells
show rather scattered and not uniform staining pattern at a given time point may provide
explanation for gradual thymic adipose involution observed during senescence.
4.2. PPARgamma impairs naïve T-cell production with age
Thymus histology data show that the medullary compartment is rescued from age-related
shrinking in case of PPARgamma deficiency (Figure 2A-D). Extended survival of this
stromal niche ensures permissive environment for sustained thymus function: naïve T-cell
production. This is indicated by elevated mTrec values showing direct correlation with
PPARgamma deficiency (Figure 3A). Of extreme importance and highlighting human
relevance, peripheral blood leukocyte hTrec values from adult FPLD3 patients (with genetic
PPARgamma deficiency) also exceed adult FPLD2 patient values (with unrelated genetic
background) despite being age-matched and disease-matched (lipodystrophy, diabetes)
(Figure 6). Of note, such metabolic disorders are known to impair thymus function indicated
by decreased hTrec values as reported by others (43, 44). For exactly this reason have we used
disease-matched controls (FPLD2 vs FPLD3) to show enhanced thymus function with
PPARgamma deficiency despite metabolic disorders. Unlike lower than physiological hTrec
values measured in FPLD2 (lamin) patients, those measured in FPLD3 (PPARgamma)
patients are within healthy human physiological range (Figure 6). Since both mTrec and
hTrec DNA loops originate from gene rearrangement during thymocte development this is
direct evidence of sustained T-cell development indicating intact thymic niche in
PPARgamma deficient animal models and human patients (38). Of note, the distribution of
thymocyte subpopulations shows identical pattern irrespective of PPARgamma status proving
that sustained, enhanced thymocyte development does not skew differentiation preference, but
rather enhances fresh, naive T-cell production of all thymocyte subtypes uniformly (Figure
3B). Finally, since sustained thymic naïve T-cell production is not restricted to a given time-
point, but rather represents a continuous trend, the peripheral blood naïve T-cell population
shows cumulative differences as it is rescued from age-driven shrinking, against the memory
T-cell population – more specifically against the effector memory T-cell pool (Figure 4B-C). 
4.3. PPARgamma hampers T-dependent immune regulation and immunity with age
Oral consumption of foreign T-depended antigen normally initiates immune tolerance
inhibiting any eliminative immune response (e.g. serum IgG), despite parallel immunization
in young adult individuals with appropriate naïve T-cell supply. Unfortunately, the
phenomenon is disrupted at senior age due to the lacking naïve T-cell pool in the Peyer’s
patches of the gut (41, 42, 45) This loss of oral tolerance (impaired immune regulation) is a
possible link to increasing food intolerance prevalence observed in the aging adult population
(46-49). However, the phenomenon may be rescued by PPARgamma deficiency despite of
age providing evidence that sustained T-cell production is necessary for efficient oral
(immune) tolerance (Figure 5A).
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Senescence-triggered decrease of naïve T-cell output also impairs T-dependent immunity. An
example in the senior human population is decreased protection from seasonal flu strains
despite annual vaccination campaigns (50-52). The phenomenon has well established animal
models (53-55). This is caused by low levels of neutralizing antibody titers due to lacking
naïve T-cells necessary during T-B cooperation to mount adequate innate immune response
against T-dependent antigens of the vaccine. This, however, is not the case with PPARgamma
deficiency (Figure 5B). Single intramuscular vaccination against seasonal flu (mimicking
human vaccination campaign) resulted in higher maximal antibody production three months
later (a typical delay in human exposure). This confirms that the cause of decreased
vaccination efficiency in the senior population is impaired T-dependent immunity due to
thymic senescence.
In our experiments we have focused on the decline of T-dependent immunity since the thymus
shows early and dramatic signs of senescence during adipose involution. This, however, is not
the case for the B-cell compartment for which aging has been reported to occur later and in a
more gradual fashion, lacking such profound histological changes (56).
PPARgamma is an enigmatic transcription factor showing unique expression pattern in both
time and space throughout the body (57). PPARgamma affects both hemopoietic and stromal
compartments during development and aging. Further dissection would require to perform
e.g. bone-marrow transplantation experiments between control and PPARgamma deficient
animals. However, PPARgamma KO animals develop severe metabolic disorders that hamper
such experiments, especially at elevated ages. 
4.5. Limitations and perspectives
We here present the long-term thymus- and T-dependent immunity-preserving effect of
systemic (genetic) loss of PPARgamma function as observed in PPARgamma deficient mouse
models and in a human rare disease (FPLD3). In both cases, there are severe metabolic
drawbacks (diabetes, dyslipidemia etc.) due to systemically lacking PPARgamma activity.
However, alternative, thymus tissue-restricted suppression of PPARgamma activity would
likely solve the issue. Of note, as reported previously, over-expression of Wnt4
glycolipoproteins by thymic epithelial cells can efficiently counteract PPARgamma (31).
Also, Wnt4 was described to travel in extracellular vesicles including exosomes and affect
thymocyte differentiation (58, 59). Hence, it is conceivable that thymic epithelium-derived,
enriched exosomes would efficiently home to the thymus and deliver their Wnt4 cargo locally
even when administered systemically. This would, in theory, allow for the natural, tissue-
specific, protein-mediated maintenance of thymic epithelial identity and prevent thymic
senescence from developing.
Although tissue senescence is ultimately inevitable, there are conditions that accelerate
thymic senescence including certain viral infections, intoxications, irradiation, chemotherapy
etc. Outcomes include increased incidence of infection, cancer and autoimmune disorder. In
any case the identification of molecular level targets for potential intervention is highly
desired. Therefore, molecular level insight into immune senescence has medical, economical
and personal relevance, all at once. 
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FIGURE LEGENDS
Figure 1.
PPARgamma expression in the adult thymus
Human FFPE thymic sections were analyzed for PPARgamma expression by
immunohistochemistry in age groups of 20-30 years called young adult (Figure 1A), 50-60
years called middle-aged (Figure 1B) and 70-80 years called senior (Figure 1C). Brown color
reaction (DAB) shows PPARgamma expression. Blue color (hematoxylin) shows nuclear
counter-stain and defines total cellular areas. The ratio of PPARgamma-expressing cellular
areas and total cellular areas is also shown for the different age groups (Figure 1D).
Immunofluorescent staining is also shown for mouse at 1 month of age called young adult and
at 15 months of age called senior (Figure 1E-F). Green color shows epithelial cells (anti-
EpCAM1-FITC), red color shows pre-adipocytes (anti-PPARgamma primary AB with Alexa-
555 secondary AB) and blue color defines nuclei (DAPI counter-stain). Please note
arrowheads pointing at double-staining (EpCAM-1+ / PPARgamma+) cells (Figure 1F). Both
stainings show expected patterns: EpCAM-1 staining presents cell surface markers, while
PPARgamma-staining shows nuclear localization (observed in magenta color due to overlap
with DAPI nuclear counter-stain on Figure 1F). For exact numerical data please refer to
Supplementary material. Significant differences are shown by asterisks (ns for not significant,
* for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
Figure 2.
Ratio of epithelial compartments in the adult thymus
Mouse thymic cryo-sections were stained differentially for medullary (anti-EpCAM1-FITC++,
anti-Ly51-PE-) and cortical (anti-Ly51-PE++, anti-EpCAM1-FITC+) epithelial compartments.
Wild-type thymus is shown at 1 month (Figure 2A) and 8 months of age (Figure 2B).
PPARgamma heterozygous (Figure 2C) and PPARgamma KO (Figure 2D) animals are shown
at 8 months of age. The ratio of medullary and cortical epithelial compartment is also shown
(Figure 2E) for both ages and genetic backgrounds. For exact numerical data please refer to
Supplementary material. Significant differences are shown by asterisks (ns for not significant,
* for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
Figure 3.
Thymocyte development in the adult thymus
Changes in level of mouse T-cell recombination excision circles (mTrec) was evaluated by
Taqman digital qPCR in wild-type, PPARgamma heterozygous and PPARgamma KO
thymocytes (Figure 3A). The columns represent mTrec values measured at 8 months divided
by those measured at 1 month for every strain. The ratio of thymocyte subpopulations was
assessed by flow-cytometry at 8 months of age in wild-type, PPARgamma heterozygous and
PPARgamma KO animals (Figure 3B). Double negative (CD4-, CD8-), double positive (CD4+,
CD8+) and single positive (CD4+ or CD8+) subpopulations are shown. For the measurement of
every sample 100,000 cells were stained and 10,000 events (parent R1 morphological
lymphocyte gate) were recorded by flow-cytometry. For exact cell numbers please refer to
Supplementary material. Significant differences are shown by asterisks (ns for not significant,
* for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
Figure 4.
T-cell subpopulations in adult peripheral blood
Peripheral blood T-cell subpopulations were evaluated by flow-cytometry at 12 months of age
in wild-type and PPARgamma heterozygous animals (KO animals decease by this age).
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Percent distribution of T-cells (CD3+), helper T-cells (CD3+, CD4+) and cytotoxic T-cells
(CD3+, CD8+) is shown by Figure 4A. Also, the percent distribution of naive T-cells (CD3+,
CD44-, CD62L+) and memory T-cells (CD3+, CD44+, CD62L+/-) was evaluated within the
CD3-gate of T-cells (Figure 4B). Further analysis of memory T-cell subpopulation shows
percent distribution of effector memory T-cells (CD3+, CD44+, CD62L-) and central memory
T-cells  (CD3+, CD44+, CD62L+) within the CD3-gate of T-cells (Figure 4C). For the
measurement of every sample 100,000 cells were stained and 10,000 events (parent R1
morphological lymphocyte gate) were recorded by flow-cytometry. For exact cell numbers
please refer to Supplementary material. Significant differences are shown by asterisks (ns for
not significant, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
Figure 5.
Functional immunological experiments in adult hosts
Oral tolerance induction capacity to ovalbumin (OVA) was assayed in wild-type and
PPARgamma heterozygous animals at 12 months of age. Animals received OVA by either
drinking water, i.p. injection, both or neither. OVA-specific IgG titers were evaluated 3 weeks
later by ELISA method (Figure 5A). The presented figure was obtained using 1:400 dilution
of serum. Mean ELISA OD values are shown for each study group. Human seasonal influenza
vaccine (3Fluart) was injected (0.1ml, 1x, i.m.) into wild-type and PPARgamma heterozygous
animals at 9 months of age. Serum IgG titers specific to a vaccine component (H1N1
A/California/7/2009 strain) were tested 3 months later by ELISA method (Figure 5B). The
presented figure was obtained using 1:50 dilution of serum. Maximal ELISA OD values are
shown for each study group. For exact numerical data please refer to Supplementary material.
Significant differences are shown by asterisks (ns for not significant, * for p ≤ 0.05, ** for p ≤
0.01, *** for p ≤ 0.001).
Figure 6.
Thymus function in adult FPLD patients
Level of human T-cell recombination excision circle (hTrec) was measured by Taqman digital
qPCR in peripheral blood leukocytes of age-matched and disease-matched rare disease
patients with FPLD2 condition (lipodystrophy due to LMNA-deficiency) and FPLD3
condition (lipodystrophy due to PPARgamma-deficiency) (Figure 6). Patient sample numbers
were n=3 for FPLD2 and n=5 for FPLD3. For exact numerical data please refer to
Supplementary material. For age-matched (approx. 50 years of age) range of healthy human
hTrec values please refer to the work of Lynch et al (38). Accordingly, the lower limit of
healthy human hTrec threshold (approx. 200 copies / mg DNA) is represented by dotted line.
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